Page last updated: 2024-10-31

midazolam and MODS

midazolam has been researched along with MODS in 11 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research Excerpts

ExcerptRelevanceReference
"To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children."9.22Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016)
"To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children."7.78The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012)
" However, midazolam given in the designated dosage did not offer any modulatory effects on hemodynamic responses, multiple organic dysfunction and survival rate in rats with endotoxemia."7.75Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide. ( Ho, ST; Liaw, WJ; Tsao, CM; Wu, CC, 2009)
"Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography."6.70[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002)
"To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children."5.22Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jerchel, IS; Knibbe, CA; Koch, BC; Mooij, MG; Tibboel, D; van Schaik, RH; Verlaat, CW; Vet, NJ, 2016)
"To assess the effect of continuous hemodiafiltration (CHDF) on ketamine and midazolam kinetics in multiple organ dysfunction syndrome (MODS)."5.09Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome. ( Ishihara, H; Matsuki, A; Okawa, H; Sakai, I; Tsubo, T, 2001)
"The recently published pharmacokinetic model for midazolam, quantifying the influence of maturation, inflammation and organ failure in children, yields unbiased clearance predictions and can therefore be used for dosing instructions in term neonates, children and adults with varying levels of critical illness, including healthy adults, but not for extrapolation to preterm neonates."3.88Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. ( Brussee, JM; de Hoog, M; de Wildt, SN; Jacqz-Aigrain, E; Knibbe, CAJ; Krekels, EHJ; Swart, EL; Tibboel, D; Valkenburg, AJ; van den Anker, JN; van Gerven, JMA; Vet, NJ, 2018)
"To determine the effect of inflammation and disease severity on midazolam pharmacokinetics (as surrogate marker of cytochrome 3A activity) and pharmacodynamics in critically ill children."3.78The effect of critical illness and inflammation on midazolam therapy in children. ( de Hoog, M; de Wildt, SN; Tibboel, D; Vet, NJ, 2012)
" However, midazolam given in the designated dosage did not offer any modulatory effects on hemodynamic responses, multiple organic dysfunction and survival rate in rats with endotoxemia."3.75Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide. ( Ho, ST; Liaw, WJ; Tsao, CM; Wu, CC, 2009)
"Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography."2.70[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002)
"Twenty critically ill patients with acute renal failure on CVVH therapy were administered either lorazepam (n = 10) or midazolam (n = 10) by continuous infusion."1.33Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ( Danhof, M; de Jongh, J; Strack van Schijndel, RJ; Swart, EL; Thijs, LG; Zuideveld, KP, 2005)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Patel, C1
Kleinig, P1
Bakker, M1
Tait, P1
Wijnsma, KL1
Schijvens, AM1
Rossen, JWA1
Kooistra-Smid, AMDM1
Schreuder, MF1
van de Kar, NCAJ1
Brussee, JM2
Vet, NJ3
Krekels, EHJ1
Valkenburg, AJ1
Jacqz-Aigrain, E1
van Gerven, JMA1
Swart, EL2
van den Anker, JN1
Tibboel, D3
de Hoog, M3
de Wildt, SN3
Knibbe, CAJ1
Mooij, MG1
Verlaat, CW1
Jerchel, IS1
van Schaik, RH1
Koch, BC1
Knibbe, CA1
Tsao, CM1
Wu, CC1
Liaw, WJ1
Ho, ST1
Poloyac, SM1
Bastien, O1
Bolon, M1
Flamens, C1
Lehot, JJ1
Boulieu, R1
de Jongh, J1
Zuideveld, KP1
Danhof, M1
Thijs, LG1
Strack van Schijndel, RJ1
De Deyne, C1
Struys, M1
Decruyenaere, J1
Creupelandt, J1
Hoste, E1
Colardyn, F1
Tsubo, T1
Sakai, I1
Okawa, H1
Ishihara, H1
Matsuki, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bispectral Index Monitoring To Guide Sedation In Patients With Non-Neurological Pathology Over 65 Years, Admitted To Intensive Care Unit: Randomized Control Trial[NCT02909010]150 participants (Anticipated)Interventional2015-05-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for midazolam and MODS

ArticleYear
Palliative sedation: A safety net for the relief of refractory and intolerable symptoms at the end of life.
    Australian journal of general practice, 2019, Volume: 48, Issue:12

    Topics: Aged; Analgesics; Conscious Sedation; Dehydration; Dyspnea; Humans; Hydromorphone; Hypnotics and Sed

2019

Trials

3 trials available for midazolam and MODS

ArticleYear
Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children.
    American journal of respiratory and critical care medicine, 2016, 07-01, Volume: 194, Issue:1

    Topics: Adolescent; Anesthetics, Intravenous; Child; Child, Preschool; Critical Illness; Female; Humans; Inf

2016
[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
    Annales francaises d'anesthesie et de reanimation, 2002, Volume: 21, Issue:9

    Topics: Adjuvants, Anesthesia; Aged; Biotransformation; Chromatography, Liquid; Female; Half-Life; Hemofiltr

2002
Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome.
    Intensive care medicine, 2001, Volume: 27, Issue:6

    Topics: Analgesics; Anti-Anxiety Agents; Female; Glasgow Coma Scale; Hemodiafiltration; Humans; Ketamine; Ma

2001

Other Studies

7 other studies available for midazolam and MODS

ArticleYear
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Pediatric nephrology (Berlin, Germany), 2017, Volume: 32, Issue:7

    Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biopsy; Blood Culture; Ceftriaxone; Escher

2017
Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.
    British journal of clinical pharmacology, 2018, Volume: 84, Issue:2

    Topics: Adult; C-Reactive Protein; Child; Critical Illness; Cytochrome P-450 CYP3A; Humans; Hypnotics and Se

2018
Effects of midazolam on organ dysfunction in rats with endotoxemia induced by lipopolysaccharide.
    Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists, 2009, Volume: 47, Issue:1

    Topics: Adjuvants, Anesthesia; Animals; Endotoxemia; Hemodynamics; Lipopolysaccharides; Male; Midazolam; Mul

2009
The effect of critical illness and inflammation on midazolam therapy in children.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2012, Volume: 13, Issue:1

    Topics: Adolescent; C-Reactive Protein; Child; Child, Preschool; Cohort Studies; Critical Illness; Cytokines

2012
Altered drug metabolism in critically ill children: a significant source of adverse effects?.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2012, Volume: 13, Issue:1

    Topics: Critical Illness; Female; Humans; Inflammation; Male; Midazolam; Multiple Organ Failure

2012
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:2

    Topics: Acute Kidney Injury; Adult; Aged; Conscious Sedation; Drug Administration Schedule; Drug Evaluation;

2005
Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients.
    Intensive care medicine, 1998, Volume: 24, Issue:12

    Topics: Analgesics, Opioid; Conscious Sedation; Critical Illness; Dose-Response Relationship, Drug; Drug Mon

1998